The CannTrust (TSX:TRST) Scandal Has Now Gotten Even Worse

The odds of CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST) losing its licence definitely went up on Monday as investors learned that its Pelham location wasn’t the only facility with problems.

Double exposure of a businessman and stairs - Business Success Concept

Image source: Getty Images

CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST) has been facing no shortage of issues lately, and things have gotten even worse for the company.

On Monday, we learned in another update from the cannabis company that it had been notified that it was once again non-compliant, this time at its Vaughan location.

CannTrust has already run into issues with its Pelham facility and is currently awaiting a decision from Health Canada on revelations that it was growing in rooms it wasn’t licenced to do so yet, with one ex-employee even stating that it had put up fake walls in order to help conceal the operations from regulators.

This latest report at Vaughan was as a result of an inspection that took place in July, after the Pelham problems came to light. The issues again relate to a lack of approval from Health Canada and also insufficient controls and procedures in place to ensure security and quality.

Deja vu for investors

In what’s likely become a bit of a joke for investors by now, new interim CEO Robert Marcovitch is already coming out with many of the same responses we’ve heard from his predecessor, Peter Aceto.

In the press release that the company issued on Monday, he stated, “We are continuing to work hard to regain the trust of Health Canada, our patients, shareholders and partners.

We have retained independent consultants who have already started addressing some of the deficiencies noted in Health Canada’s report. We are looking at the root causes of these issues and will take whatever remedial steps are necessary to bring the Company into full regulatory compliance as quickly as possible.”

The response was very similar to Friday’s response, in which investors learned that the company’s auditors were withdrawing their reports from CannTrust’s latest financial:

“We will continue cooperating with our auditor and regulators, and take whatever steps are necessary to restore full trust in the Company’s regulatory compliance. Our medical patients, customers, shareholders and employees deserve nothing less.”

At some point, these words begin to mean less and less, and I think we’ve already reached that point. Let’s not forget that as of Monday, investors were still waiting for a “root cause analysis” that Aceto said the company was working on about a month ago.

Once again, the company’s current CEO is talking about uncovering “root causes” for problems at another facility.

This all suggests that the company hasn’t made the changes necessary to its operations, even after regulators found problems at one location.

This only makes it less likely that Health Canada won’t take away the company’s licence, as at this point it would be difficult to have much trust in the company’s operations.

Bottom line

If there was any reason to have hope in the company’s turnaround, it should be gone by now. The one saving grace would have been if CannTrust were able to demonstrate to regulators and investors that it had at least fixed its operations and that things were in a better place and that Pelham was an anomaly.

Instead, it’s shown that the issues facing the company are more widespread than just one location.

The stock is a very risky buy today, and it’s hard to even come up with a reason of why it might be worth investing in.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »